Targacept, Inc. (TRGT)
-NasdaqGS 5.48 
0.07(1.29%) May 17, 4:00PM EDT|After Hours
:
5.48 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 5.41 |
|---|
| Open: | 5.42 |
|---|
| Bid: | 5.13 x 1500 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.50 |
|---|
| Beta: | 1.78 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 5.39 - 5.52 |
|---|
| 52wk Range: | 3.85 - 5.52 |
|---|
| Volume: | 750,492 |
|---|
| Avg Vol (3m): | 174,816 |
|---|
| Market Cap: | 184.22M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Targacept gets a show of supportoptionMONSTER(Wed, May 15)
- TARGACEPT INC FinancialsEDGAR Online Financials(Tue, May 14)
- TARGACEPT INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Targacept's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Targacept Earnings: Here’s Why Investors are Ambivalent Nowat Wall St. Cheat Sheet(Tue, May 7)
- Targacept, Inc. Earnings Call scheduled for 8:30 am ET todayCCBN(Tue, May 7)
- Targacept Reports First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 7)
- Q1 2013 Targacept, Inc. Earnings Release - Before Market OpenCCBN(Tue, May 7)
- TARGACEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
- Unusual trade is bullish on TargaceptoptionMONSTER(Mon, May 6)
- Targacept to Report First Quarter 2013 Financial Results on May 7, 2013Business Wire(Tue, Apr 30)
- Targacept completes recruitment for Phase 2b study of TC-1734theflyonthewall.com(Mon, Apr 29)
- Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s DiseaseBusiness Wire(Mon, Apr 29)
- Targacept Announces Participation in Upcoming ConferencesBusiness Wire(Mon, Apr 22)
- Targacept Completes Recruitment in Phase 2b Schizophrenia Trial of TC-5619Business Wire(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 4.72 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.36 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.37 |
|---|
| Mean Recommendation*: | 2.8 |
|---|
| PEG Ratio (5 yr expected): | 0.02 |
|---|
Business Summary
Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system.
View More